A COST-UTILITY ANALYSIS OF DEGARELIX IN THE TREATMENT OF ADVANCED HORMONE-DEPENDENT PROSTATE CANCER IN SCOTLAND

被引：1
作者：
Fisher, D. [1 ]
Brereton, N. J. [1 ]
Kildegaard Nielsen, S. [2 ]
Tate, E. [3 ]
机构：
[1] BresMed Hlth Solut, Sheffield, S Yorkshire, England
[2] Ferring Int Ctr SA, St Prex, Switzerland
[3] Hayward Med Commun, Newmarket, Suffolk, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1201
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A452 / A452
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer
    Lu, Lanting
    Peters, Jaime
    Roome, Chris
    Stein, Ken
    BJU INTERNATIONAL, 2012, 109 (08) : 1183 - 1197
  • [2] An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
    Rick, Ferenc G.
    Block, Norman L.
    Schally, Andrew V.
    ONCOTARGETS AND THERAPY, 2013, 6 : 391 - 402
  • [3] A COST-UTILITY ANALYSIS OF DEGARELIX IN THE TREATMENT OF PROSTATE CANCER IN CHINA
    Yang, F.
    Du, X.
    Xuan, J.
    Fei, J.
    VALUE IN HEALTH, 2019, 22 : S35 - S36
  • [4] Re: Cost-Effectiveness Analysis of Degarelix for Advanced Hormone-Dependent Prostate Cancer Editorial Comment
    Penson, David F.
    JOURNAL OF UROLOGY, 2013, 189 (02) : 531 - 531
  • [5] The utility of a model-based cost-effectiveness analysis of degarelix versus leuprolide in the therapy of hormone-dependent advanced prostate cancer
    Perachino, Massimo
    Eandi, Mario
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2013, 14 (03) : 131 - 146
  • [6] Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis
    Yan, Jianzhou
    Li, Caiyun
    Zhang, Xuefang
    Cheng, Luyan
    Ding, Ruilin
    Zhang, Lingli
    FRONTIERS IN PUBLIC HEALTH, 2022, 10 : 942800
  • [7] Interpreting cost-utility analysis of prostate cancer treatment
    James B. Yu
    Nature Reviews Urology, 2013, 10 : 129 - 131
  • [8] Interpreting cost-utility analysis of prostate cancer treatment
    Yu, James B.
    NATURE REVIEWS UROLOGY, 2013, 10 (03) : 129 - 131
  • [9] Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands
    Roshani, Hossain
    Roos, Erik P. M.
    Elzevier, Henk W.
    van de Beek, Cees
    van Winkel, Peter
    Pelger, Rob C. M.
    CURRENT UROLOGY, 2021, 15 (04) : 204 - 208
  • [10] Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Lesley Uttley
    Sophie Whyte
    Timothy Gomersall
    Shijie Ren
    Ruth Wong
    Duncan Chambers
    Paul Tappenden
    PharmacoEconomics, 2017, 35 : 717 - 726
12345